Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Summary

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

Timeline

Start

2005-11

Primary completion

—

Completion

2007-06

Drugs

Indications